Source: Health Products Regulatory Authority (IE) Revision Year: 2015 Publisher: Ferring Ireland Ltd, United Drug House, Magna Drive, Magna Business Park, Citywest Road, Dublin 24, Ireland
Desmospray, Desmopressin Nasal Spray.
| Pharmaceutical Form |
|---|
|
Nasal spray, solution. Clear, colorless solution. |
Desmospray contains 10 micrograms of demopressin acetate per actuation (0.1 ml), equivalent to 8.9 micrograms desmopressin.
Excipients: 1ml Desmospray contains 0.1 mg benzalkonium chloride.
For the full list of excipients see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Desmopressin |
Desmopressin is a structural analogue of vasopressin in which the antidiuretic activity has been enhanced by the order of 10, while the vasopressor effect has been reduced by the order of 1500. The clinical advantage of this highly changed ratio of antidiuretic to vasopressor effect is that clinically active antidiuretic doses are far below the threshold for a vasopressor effect. |
| List of Excipients |
|---|
|
Benzalkonium chloride solution |
The spray pack comprises of a 10ml amber glass injection vial fitted with a snap-on tamper-proof pre-compression spray pump, to which a 20 mm nasal applicator is attached. The fill volume is 7.1ml including overage to allow delivery of 60 doses of 0.1ml.
Ferring Ireland Ltd, United Drug House, Magna Drive, Magna Business Park, Citywest Road, Dublin 24, Ireland
PA1009/005/001
Date of first authorisation: 09 July 1987
Date of last renewal: 09 July 2007
| Drug | Countries | |
|---|---|---|
| DESMOSPRAY | Ireland, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
